Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine
Notice bibliographique
Résumé
Advances in regenerative medicine are generating transformative solutions to many of today's incurable medical conditions. These advances have resulted from interdisciplinary efforts across the biological sciences, medicine, and engineering, changes in the regulatory environment—including the passage of the 21st Century Cures Act—and ongoing efforts to drive industry standardization. Increasingly, these advances have been catalyzed by regional initiatives around the U.S. and the world aimed at expediting the discovery, translation, and commercialization of transformative treatments. The proliferation of new models like the Centre for Commercialization of Regenerative Medicine (CCRM) in Canada, the California Institute for Regenerative Medicine (CIRM), and the Advanced Regenerative Manufacturing Institute (ARMI) in New Hampshire, among others, has inspired the creation of the Florida Organization for Regenerative Medicine (FORM), a nonprofit organization with a mission to facilitate translational research, commercialization, education, and therapeutic validation in the area of regenerative medicine with the ultimate aim of improving patient outcomes, creating high-quality jobs, and accelerating innovation through collaboration in the State of Florida and beyond. FORM is comprised of multiple strong and complementary clinical and research groups within Florida, including (from North to South) the Mayo Clinic's Center for Regenerative Medicine; the University of Florida's Center for Regenerative Medicine, which operates across the university and is based in the College of Medicine (CoM), and Institute for Cell and Tissue Science and Engineering (ICTSE) in the College of Engineering (CoE); Nova Southeastern University's Cell Therapy Institute (CTI); Florida Atlantic University's Center for Molecular Biology and Biotechnology (CMBB); and the University of Miami's Diabetes Research Institute (DRI), Cell Transplant Center (CTC), and Interdisciplinary Stem Cell Institute (ISCI). Furthermore, FORM aims to convene nonprofit organizations and for-profit companies integral to the state's regenerative medicine industry, including 42Bio, LLC, Akron Biotechnology, LLC, AxoGen, Corp, BioFlorida, Inc., Brammer Bio, LLC, CytoSen Therapeutics, Inc., Iovance Biotherapeutics, Inc., Lifelink Foundation, Inc., Leidos Health (subsidiary of Leidos, Inc.), Longeveron, LLC, RTI Surgical, Inc., and Vestion, Inc., among others. FORM aims to leverage state, federal, and philanthropic funding to foster strong and integrative collaboration among academic, government and private sectors in order to accelerate activities necessary to establish the State of Florida as one of the hubs of this nascent and important industry. These activities include supporting translational research, facilitating the commercialization of therapeutics and engineered tissues, creating and driving workforce development initiatives, and validating novel treatments to support the safe and efficacious uptake of regenerative medicine. The State of Florida is home to various institutions and companies active in the regenerative medicine space. Given the strength of its research and clinical institutions, the dynamism of its industrial base, and its size and demographics, the state can and should be a key driver in the emergence of this new paradigm in human health. FORM endeavors to convene the state's leading institutions and companies to drive economic growth, accelerate innovation, and improve patient outcomes through the development and commercialization of regenerative therapies.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,005 | 0,019 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,009 | 0,005 |
| Communication savante | 0,004 | 0,006 |
| Science ouverte | 0,002 | 0,002 |
| Intégrité de la recherche | 0,062 | 0,041 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,006 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».